Security key
64136E102
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP)
CUSIP: 64136E102
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Shares outstanding
- 5,420,049
- Total 13F shares
- 1,757,860
- Share change
- +180,706
- Total reported value
- $7,153,657
- Price per share
- $4.07
- Number of holders
- 19
- Value change
- +$756,052
- Number of buys
- 9
- Number of sells
- 8
Report period
Q1 2026
Institutions
19
Top holders
10
NEUP full security history
Previous quarter: Q4 2025
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 64136E102
Recent filing periods:
Top shareholders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
3/4/5
13D/G
13F
|
10%+ Owner · Company |
16%
from 13D/G
|
875,328
|
$10,381,390 | — | 21 Oct 2025 | |
| Shay Capital LLC |
13D/G
13F
|
Company |
7.3%
|
171,629
|
$2,035,520 | $0 | 24 Oct 2025 | |
| Coastlands Capital LP |
13D/G
|
— |
5.1%
|
120,000
|
$1,423,200 | $0 | 05 Nov 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,033,796
|
$5,365,401 | $0 | 31 Dec 2024 | |
| Apeiron Investment Group Ltd. |
13D/G
|
— |
4.5%
|
72,618
|
$376,887 | $0 | 24 Jan 2025 | |
| Baselake Partners, LP |
13D/G
|
— |
4.1%
|
222,222
|
$862,110 | $0 | 31 Dec 2025 | |
| AdvisorShares Investments LLC |
13F
|
Company |
2.5%
|
134,194
|
$520,673 | — | 31 Dec 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.92%
|
50,000
|
$194,000 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.88%
|
47,443
|
$184,079 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.55%
|
30,000
|
$116,400 | — | 31 Dec 2025 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.49%
|
26,500
|
$102,000 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.39%
|
20,950
|
$81,286 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
17,303
|
$67,135 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.31%
|
16,597
|
$64,396 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.27%
|
14,750
|
$57,230 | — | 31 Dec 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.26%
|
14,000
|
$54,320 | — | 31 Dec 2025 | |
| Persistent Asset Partners Ltd |
13F
|
Company |
0.25%
|
13,403
|
$52,004 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.22%
|
12,008
|
$46,591 | — | 31 Dec 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.21%
|
11,207
|
$43,480 | — | 31 Dec 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
0.18%
|
10,027
|
$38,905 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
1,652
|
$6,409 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.03%
|
1,400
|
$5,432 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0%
|
202
|
$783 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
58
|
$225 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
18
|
$70 | — | 31 Dec 2025 | |
| Spyros Papapetropoulos |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
74,088
|
$612,707 | — | 27 Aug 2025 | |
| Alan Fisher |
3/4/5
|
Director |
—
class O/S missing
|
30,731
|
— | — | 20 Jan 2026 | |
| Jane Ryan |
3/4/5
|
Director |
—
class O/S missing
|
15,550
|
— | — | 20 Jan 2026 | |
| David Ian Wilson |
3/4/5
|
Director |
—
class O/S missing
|
15,412
|
— | — | 20 Jan 2026 | |
| Peter Miles Winston Davies |
3/4/5
|
Director |
—
class O/S missing
|
15,320
|
— | — | 20 Jan 2026 |
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) as of Q1 2026
As of 31 Mar 2026,
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,757,860 shares.
The largest 10 holders included
Lynx1 Capital Management LP, AdvisorShares Investments LLC, Shay Capital LLC, Balyasny Asset Management L.P., VANGUARD CAPITAL MANAGEMENT LLC, Squadron Capital Management LLC, GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, VANGUARD FIDUCIARY TRUST CO, and ADAR1 Capital Management, LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q1 2026 holders
19
Holder diff
-2
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.